Menu Search
Equities

Kiromic Biopharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
5JU0:MUN

Kiromic Biopharma Inc

Actions
  • Price (EUR)5.19
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta4.6857
Data delayed at least 15 minutes, as of Mar 10 2023 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company. The Company is engaged in developing an allogeneic Gamma Delta T-cell therapy featuring proprietary end-to-end bioinformatic, artificial intelligence (AI) targeting and manufacturing technologies to address solid tumors. It has five clinical programs to study its key product candidates: Deltacel-01, Alexis-ISO-1, Alexis-PRO-1, Isocel combination, and Procel combination. Deltacel is its first allogeneic, off-the-shelf GDT cell-based product in Phase I clinical-stage. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells, and they are in the preclinical development stage. Its Isocel product candidate consists of engineered GDTs that target Mesothelin Isoform 2, a target that has been discovered and prioritized using its Diamond AI bio-informatic platform. Its Procel product candidate consists of engineered GDTs that target PD-L1.

  • Revenue in USD (TTM)0.00
  • Net income in USD-33.73m
  • Incorporated2016
  • Employees44.00
  • Location
    Kiromic Biopharma Inc7707 Fannin St., Suite 140HOUSTON 77054United StatesUSA
  • Phone+1 (832) 968-4888
  • Fax+1 (302) 655-5049
  • Websitehttps://kiromic.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.